0570.HK
Bayzed operates healthcare

China Traditional Chinese Medicine Holdings Co. Ltd. (0570.HK) on Wednesday warned that it expects to report its profit for all of 2024 fell by 90% to 100%, while its adjusted profit also fell by 50% to 60% year-on-year.

The company’s profit totaled 1.4 billion yuan ($191 million) in 2023, according to its latest annual report, meaning last year’s profit will fall to 140 million yuan or even to nil.

The company blamed the big drop on price cuts required by China’s centralized procurement system, as well as intensifying market competition and relatively high costs of medicinal materials. It added that credit, goodwill and plant impairment costs increased during the period. Its profit was also affected by remedial taxes on some of its subsidiaries last year.

Shares of China Traditional Chinese Medicine fell 6.3% to HK$1.92 in Thursday trading after the profit warning’s release.

By Lau Chi HangTo subscribe to Bamboo Works weekly free newsletter, click  here

Recent Articles

illustration of a Pop Mart's Labubu

Labubu fever, and a skincare brawl

An early edition toy based on the red-hot Labubu character has fetched a record $150,000 in a recent auction. What's driving the craze, and is it sustainable? And a high-profile tussle between two leading skincare brands has left one of them bruised, with its stock down 30%. How can investors steer clear of this kind of damage?
Tencent Music acquiring Ximalaya, shoring up its weak long-audio flank

Tencent Music scales audio heights with Ximalaya purchase

While short videos are all the rage lately, Tencent Music’s latest acquisition bolsters its position in the strategically important market for long-form audio content Key Takeaways: Tencent Music will pay…